Nelly R Mugo1, Kenneth Ngure, Michael Kiragu, Elizabeth Irungu, Nduku Kilonzo. 1. aCenter for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya bDepartment of Global Health, University of Washington, Seattle, WA, USA cPartners in Health Research and Development, Thika dDepartment of Public Health, Jomo Kenyatta University of Agriculture and Technology, Juja eLVCT-Health fNational AIDS Control Council, Nairobi, Kenya.
Abstract
PURPOSE OF REVIEW: An investment in preexposure prophylaxis (PrEP) delivery must have public health impact in reducing HIV infections. Sustainable delivery of PrEP requires policy, integration of services, and synergy with other existing HIV prevention programs. This review discusses key policy and programmatic considerations for implementation and scale up of PrEP in Africa. RECENT FINDINGS: PrEP delivery has been delayed by concerns about adherence and delivery in 'real world' settings. Demonstration projects and clinical service delivery models are providing evidence of PrEP effectiveness with an impact much higher than that found in randomized clinical trials. Data confirm that PrEP uptake, adherence, and retention has been high, more so by persons who perceive themselves at high risk for HIV infection, and PrEP is well tolerated. PrEP delivery is more than dispensation of a pill and programs should address other risk drivers, which differ by population. In Africa, barriers to PrEP uptake and adherence include stigma among MSM and low HIV risk perception among young women. Additional data have provided insight into optimal points of service delivery, provider training requirements and quality assurance needs. Of the 2 million new HIV infections in 2014, 70% were in Africa. PrEP use is not lifelong, and use limited to periods of risk may be both effective and cost-effective for the continent. SUMMARY: HIV prevention programs should determine strategies to identify those at substantial risk for HIV infection, formulate and deliver PrEP in combination with interventions that target social drivers of HIV vulnerability specific to each population. Policy guidance for optimal combination of interventions and service delivery avenues, clinical protocols, health infrastructure requirements are required. Cost-effectiveness and efficiency data are essential for policy guidance to navigate ethical questions over use of antiretroviral therapy for HIV-negative individuals when treatment coverage has not been attained in many parts of Africa. Countries need to invest in purposeful advocacy at both local and global forums. Failure to implement PrEP will be a failure to protect future generations.
PURPOSE OF REVIEW: An investment in preexposure prophylaxis (PrEP) delivery must have public health impact in reducing HIV infections. Sustainable delivery of PrEP requires policy, integration of services, and synergy with other existing HIV prevention programs. This review discusses key policy and programmatic considerations for implementation and scale up of PrEP in Africa. RECENT FINDINGS: PrEP delivery has been delayed by concerns about adherence and delivery in 'real world' settings. Demonstration projects and clinical service delivery models are providing evidence of PrEP effectiveness with an impact much higher than that found in randomized clinical trials. Data confirm that PrEP uptake, adherence, and retention has been high, more so by persons who perceive themselves at high risk for HIV infection, and PrEP is well tolerated. PrEP delivery is more than dispensation of a pill and programs should address other risk drivers, which differ by population. In Africa, barriers to PrEP uptake and adherence include stigma among MSM and low HIV risk perception among young women. Additional data have provided insight into optimal points of service delivery, provider training requirements and quality assurance needs. Of the 2 million new HIV infections in 2014, 70% were in Africa. PrEP use is not lifelong, and use limited to periods of risk may be both effective and cost-effective for the continent. SUMMARY: HIV prevention programs should determine strategies to identify those at substantial risk for HIV infection, formulate and deliver PrEP in combination with interventions that target social drivers of HIV vulnerability specific to each population. Policy guidance for optimal combination of interventions and service delivery avenues, clinical protocols, health infrastructure requirements are required. Cost-effectiveness and efficiency data are essential for policy guidance to navigate ethical questions over use of antiretroviral therapy for HIV-negative individuals when treatment coverage has not been attained in many parts of Africa. Countries need to invest in purposeful advocacy at both local and global forums. Failure to implement PrEP will be a failure to protect future generations.
Authors: Robert M Grant; Peter L Anderson; Vanessa McMahan; Albert Liu; K Rivet Amico; Megha Mehrotra; Sybil Hosek; Carlos Mosquera; Martin Casapia; Orlando Montoya; Susan Buchbinder; Valdilea G Veloso; Kenneth Mayer; Suwat Chariyalertsak; Linda-Gail Bekker; Esper G Kallas; Mauro Schechter; Juan Guanira; Lane Bushman; David N Burns; James F Rooney; David V Glidden Journal: Lancet Infect Dis Date: 2014-07-22 Impact factor: 25.071
Authors: Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum Journal: N Engl J Med Date: 2012-07-11 Impact factor: 91.245
Authors: Kenneth Ngure; Jared M Baeten; Nelly Mugo; Kathryn Curran; Sophie Vusha; Renee Heffron; Connie Celum; Bettina Shell-Duncan Journal: AIDS Care Date: 2014-04-29
Authors: Roger Ying; Monisha Sharma; Renee Heffron; Connie L Celum; Jared M Baeten; Elly Katabira; Nulu Bulya; Ruanne V Barnabas Journal: J Int AIDS Soc Date: 2015-07-20 Impact factor: 5.396
Authors: Noah Kiwanuka; Ali Ssetaala; Annet Nalutaaya; Juliet Mpendo; Matthias Wambuzi; Annet Nanvubya; Simon Sigirenda; Paul Kato Kitandwe; Leslie Elizabeth Nielsen; Apolo Balyegisawa; Pontiano Kaleebu; Josephine Nalusiba; Nelson Kaulukusi Sewankambo Journal: PLoS One Date: 2014-05-27 Impact factor: 3.240
Authors: Elise M van der Elst; Adrian D Smith; Evanson Gichuru; Elizabeth Wahome; Helgar Musyoki; Nicolas Muraguri; Greg Fegan; Zoe Duby; Linda-Gail Bekker; Bonnie Bender; Susan M Graham; Don Operario; Eduard J Sanders Journal: J Int AIDS Soc Date: 2013-12-02 Impact factor: 5.396
Authors: Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill Journal: Lancet Date: 2015-09-09 Impact factor: 79.321
Authors: Cheryl Hendrickson; Lawrence Long; David van de Vijver; Charles Boucher; Heidi O'Bra; Cassidy W Claassen; Mwansa Njelesani; Crispin Moyo; Daliso B Mumba; Hasina Subedar; Lloyd Mulenga; Sydney Rosen; Brooke E Nichols Journal: Lancet HIV Date: 2020-01-31 Impact factor: 12.767
Authors: Sheree R Schwartz; Joel Chavez Ortiz; Justin D Smith; Laura K Beres; Aaloke Mody; Ingrid Eshun-Wilson; Nanette Benbow; Deepthi P Mallela; Stephen Tan; Stefan Baral; Elvin Geng Journal: J Acquir Immune Defic Syndr Date: 2022-07-01 Impact factor: 3.771
Authors: Maria Pyra; Jessica E Haberer; Renee Heffron; Lara Kidoguchi; Elizabeth R Brown; Elizabeth A Bukusi; Stephen Asiimwe; Connie Celum; Elly Katabira; Nelly R Mugo; Jared M Baeten Journal: J Acquir Immune Defic Syndr Date: 2018-01-01 Impact factor: 3.731
Authors: Daniel E Sack; Caroline De Schacht; Paula Paulo; Erin Graves; Almiro M Emílio; Ariano Matino; Carlota L Fonseca; Arifo U Aboobacar; Sara Van Rompaey; Carolyn M Audet Journal: Glob Health Action Date: 2021-01-01 Impact factor: 2.640
Authors: Daniel K Were; Abednego Musau; Kaitlyn Atkins; Prakriti Shrestha; Jason Reed; Kelly Curran; Diwakar Mohan Journal: Lancet HIV Date: 2021-07-12 Impact factor: 16.070